Flerie writes down Empros Pharma stake, cuts NAV by SEK 2.66 per share

Bitget2026/09/30 13:53

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Flerie wrote down the value of its 79% stake in Empros Pharma, citing low prospects of realizing value from development projects.
The impairment cuts net asset value by SEK 2.66 per share under the investor’s conservative valuation policy.
Empros’ lead asset EMP16 is Phase 3-ready, though required trial scope and GLP-1 competition have hindered financing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Flerie AB published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to media reports, the capacity review work by OPEC+ has been delayed. Originally scheduled to be completed by the end of September 2026, it has now been postponed to mid-November. This theoretically still allows OPEC+ to discuss the related results at the plenary meeting in late November. The independent capacity assessment results will directly affect the production caps approved for each member country, and some member countries have already shown significant disagreements regarding quotas, putting pressure on the alliance’s stability.

华尔街见闻•2026/10/02 16:36